ATLN
Atlantic International Corp.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$0.90
+0.00%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 583.0M | 435.9M | 442.6M | 401.4M | 441.5M |
| Cost of Revenue | 526.7M | 389.9M | 395.4M | 354.5M | 387.3M |
| Gross Profit | 56.2M | 46.0M | 47.2M | 46.9M | 54.2M |
| Operating Expenses | |||||
| R&D Expense | — | — | — | — | — |
| SG&A Expense | 103.9M | 91.3M | 64.0M | 45.4M | 42.3M |
| General & Admin Expense | — | — | — | 44.5M | 41.4M |
| Selling & Marketing Expense | — | — | — | 962.6K | 859.5K |
| Other Expenses | 8.0M | 4.9M | 5.0M | 4.9M | 6.0M |
| Total Operating Expenses | 111.9M | 96.2M | 69.0M | 50.3M | 48.2M |
| Cost and Expenses | 638.6M | 486.1M | 464.4M | 404.8M | 435.6M |
| Operating Income (EBIT) | (55.7M) | (50.2M) | (21.8M) | (3.5M) | 6.0M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | 44.9K |
| Interest Expense | 11.4M | 9.2M | 12.0M | 17.5M | 90.7K |
| Net Interest Income | (11.4M) | (9.2M) | (12.0M) | (17.5M) | (45.9K) |
| Other Non-Op Income/Expense | (23.7M) | (9.2M) | (108.3M) | (17.7M) | (8.4M) |
| Non-Operating Income (excl Interest) | 12.3M | — | 96.3M | 150.1K | (894.1K) |
| EBT (Pre-Tax Income) | (79.4M) | (59.4M) | (130.1M) | (21.2M) | (2.4M) |
| Income Tax Expense | (48.8K) | 34.0K | 5.4M | (5.9M) | 808.4K |
| Bottom Line | |||||
| Net Income | (79.4M) | (59.4M) | (135.5M) | (15.3M) | (3.2M) |
| Earnings from Cont. Ops | (79.4M) | (59.4M) | (135.5M) | (15.3M) | (3.2M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (79.4M) | (59.4M) | (135.5M) | (15.3M) | (3.2M) |
| Per Share | |||||
| Basic EPS | ($1.32) | ($1.08) | ($3.68) | ($0.60) | ($0.19) |
| Diluted EPS | ($1.32) | ($1.08) | ($3.68) | ($0.60) | ($0.17) |
| Revenue Per Share | $7.88 | $7.95 | $12.03 | $15.79 | $20.35 |
| Shares | |||||
| Basic Shares Outstanding | 74.0M | 54.8M | 36.8M | 25.4M | 21.7M |
| Diluted Shares Outstanding | 74.0M | 54.8M | 36.8M | 25.4M | 24.1M |
| Profitability Metrics | |||||
| EBITDA | (58.1M) | (43.6M) | (113.1M) | 1.4M | 11.9M |
| D&A | 9.9M | 6.6M | 5.0M | 5.0M | 5.1M |
| EBIT | (68.0M) | (50.2M) | (118.1M) | (3.6M) | 6.9M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026